{"id":"NCT00331864","sponsor":"Novartis","briefTitle":"SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration","officialTitle":"A Phase IIIb, Open-label, Multi-center 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of Ranibizumab (0.3 mg and/or 0.5 mg) in Patients With Subfoveal Choroidal Neovasculariza-tion Secondary to Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2006-05-31","resultsPosted":"2011-01-04","lastUpdate":"2011-02-18"},"enrollment":531,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Age Related Macular Degeneration","Choroidal Neovascularization"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":["rhuFab V2"]}],"arms":[{"label":"Ranibizumab","type":"EXPERIMENTAL"}],"summary":"Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A. This study will assess the safety and efficacy of ranibizumab administered on an as-needed dosing regimen in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).","primaryOutcome":{"measure":"Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye","timeFrame":"Baseline through end of study (12 month treatment period)","effectByArm":[{"arm":"Ranibizumab Non-ANCHOR","deltaMin":48.5,"sd":null},{"arm":"Ranibizumab ANCHOR","deltaMin":38.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Switzerland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":80,"n":513},"commonTop":["Visual acuity reduced (Study eye)","Retinal haemorrhage (Study eye)","Intraocular pressure increased (Study eye)","Conjunctival haemorrhage (Study eye)","Visual acuity reduced (Fellow eye)"]}}